News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Putnam Associates, Inc.'s John A. Gordon to Moderate Panel and Speak at Harvard Business School 2010 7th Annual Healthcare Conference


2/9/2010 11:03:28 AM

January 29, 2010 -- Putnam Associates, a Boston-based strategy consulting firm serving the biotechnology and pharmaceutical industries globally, is pleased to announce that John A. Gordon, Partner, will be a moderator and speaker at the Harvard Business School 7th Annual Healthcare Conference (www.hbshealthcareclub.org) entitled, “Policy Reform: An Inflection Point for Healthcare Management?” held on Saturday, January 30, 2010, 8:00 a.m. – 5:30 p.m. at Harvard Business School.

John Gordon will moderate the pharmaceuticals and biotechnology panel, “How Will IP Shape Growth?” taking place at 1:40 pm - 2:55 pm. In addition to Mr. Gordon, panelists include: Labeeb Abboud, SVP and General Counsel, International AIDS Vaccine Initiative; Sean Maduck, Senior Manager, Market Analysis & Strategy, Genentech; and Kevin Sheridan, Managing Director, Healthcare Investment Banking, Jefferies & Company.

A dialogue will occur around these issues:

• How healthcare reform, and in particular biosimilar pathways, will impact and shape the industry in the next decade

• The challenge of balancing the needs between incentive for innovation and widespread access for public health

• The ever increasing importance of biotechnology innovation as an engine of growth for the industry

• The challenge of enforcing IP protection in global nations where respect and enforcement of IP rights is non-existent

• Growth trends drivers and challenges for biopharma product development

John Gordon has been with Putnam Associates since 1992, and has over 20 years of strategy consulting experience. For more than 17 years, he has counseled senior executives at numerous leading pharmaceutical and biotechnology companies, providing strategic support and recommendations on a wide array of issues, including pricing and reimbursement, health economics and outcomes research, new product commercialization, clinical trial development, and sales force optimization strategies. John has extensive experience in specialty pharmaceutical markets that comprise Oncology, Immunology, Cardiovascular Disease, and Anti-Infectives. He is published in peer-review literature as a co-author on a study examining the cost effectiveness of a novel immunological agent used in solid organ transplantation. Prior to joining Putnam, John worked for an economics consulting firm providing expert testimony in matters of corporate and personal litigation. Currently John serves on the Board of Directors for the National Tay-Sachs & Allied Diseases Association, Inc. John earned a BA in economics summa cum laude from Tufts University and an MBA from Harvard Business School.

Putnam Associates (www.putassoc.com) is a strategy consulting firm headquartered in Boston, founded in 1988, advising the pharmaceutical, biotechnology, diagnostics, and medical device industries on a global basis. Two decades of experience and focus in their industries enable them to create significant value for their clients. Creative and disciplined strategy development processes blend with deep market knowledge for one purpose: to help their clients succeed. The company’s partnership includes: Kevin J. Gorman, Managing Partner (BA, Boston College; MBA, Harvard Business School); Richard J. Tinsley, Partner (BA, Wharton School, University of Pennsylvania; MA, Stanford University; MBA, Stanford University); John A. Gordon, Partner (BA, summa cum laude, Tufts University; MBA, Harvard Business School); Eric C. Auger, Partner (BA, Providence College; MA, Boston University); and Domenick Bertelli, Partner (AB, Harvard University; MBA, MIT Sloan School of Management).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES